LLY
Eli Lilly and Company
LLY has the edge over PGNY overall, supported by stronger fundamentals and lower modeled downside.
PGNY
Progyny, Inc.
PGNY offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PGNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
PGNY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PGNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $36.58 | — |
| Cheap | 32x | $34.56 | -5.5% |
| Current | 34x | $36.58 | — |
| Fair | 43x | $46.46 | +27% |
| Expensive | 91x | $98.79 | +170% |
Historical ranges are pointers, not guarantees.
PGNY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PGNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PGNY, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PGNY on earnings, with more consistent year-over-year improvement.
PGNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.54 | +41% |
| Q3 2026 | $1.09 | +73% |
| Q2 2026 | $0.92 | +56% |
| Q1 2026 | $0.77 | +35% |
| Q4 2025 | $0.65 | +14% |
| Q3 2025 | $0.63 | +8.6% |
| Q2 2025 | $0.59 | -6.3% |
| Q1 2023 | $0.43 | -23% |
| Q4 2022 | $0.30 | -55% |
PGNY earned $1.09 per share over the past year, up 73% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PGNY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PGNY on profitability, with a higher operating margin.
PGNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $341.3M | +8.9% |
| Q2 2026 | $350.5M | +5.3% |
| Q1 2026 | $328.5M | +1.4% |
| Q4 2025 | $318.4M | +6.7% |
| Q3 2025 | $313.3M | +9.3% |
| Q2 2025 | $332.9M | +9.5% |
| Q1 2025 | $324M | +17% |
| Q4 2024 | $298.4M | +11% |
PGNY's revenue has grown year over year every quarter since late 2020: $341M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +3.4 points |
| Q2 2026 | 11% | +4.1 points |
| Q1 2026 | 11% | +3.3 points |
| Q4 2025 | 4.8% | -0.5 points |
| Q3 2025 | 6.9% | +2.5 points |
| Q2 2025 | 7.3% | +0.5 points |
| Q1 2025 | 7.5% | +0.8 points |
| Q4 2024 | 5.3% | +0.2 points |
PGNY's operating margin was 10% last quarter, up 3.4 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PGNY on cash flow, with more consistent year-over-year improvement.
PGNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.2M | +2.7% |
| Q2 2026 | $44.2M | -12% |
| Q1 2026 | $39.6M | -16% |
| Q4 2025 | $48.6M | -3.3% |
| Q3 2025 | $46M | +7.6% |
| Q2 2025 | $50.2M | -10% |
| Q1 2025 | $47M | +89% |
| Q4 2024 | $50.3M | +36% |
PGNY generated $180M in free cash flow over the past year, down 7.1% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PGNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -969K shares |
| 1 year | -10% | -9.1M shares |
| 3 years | -20% | -19.7M shares |
| 5 years | -19% | -19.2M shares |
| Available history | +26% | +17M shares |
PGNY has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $82.8M |
| Q2 2026 | $30M |
| Q1 2026 | $118.6M |
| Q4 2025 | $81.7M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $55.1M |
PGNY spent $313M buying back its own shares over the past year, about six times what it spent the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PGNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
PGNY has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PGNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
PGNY's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PGNY PE vs Healthcare Sector
| Metric | PGNY | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 21 | 29 | 8 pts below |
PGNY has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
PGNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.4 | 25% above |
| 20 week MA | $28.8 | 27% above |
| 50 week MA | $25.0 | 46% above |
| 100 week MA | $23.3 | 57% above |
| 200 week MA | $27.3 | 34% above |
PGNY has climbed back above all five of its weekly moving averages, and it's now 34% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
PGNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $42.2 | +51% |
| 2021 | $42.2 | $51.5 | +22% |
| 2022 | $51.5 | $30.8 | -40% |
| 2023 | $30.8 | $37.2 | +21% |
| 2024 | $37.2 | $16.9 | -55% |
| 2025 | $16.9 | $25.8 | +53% |
| 2026 YTD | $25.8 | $36.6 | +42% |
PGNY has the edge over LLY on returns for 2026, with the stronger performance.